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ABSTRACT
Objectives: To review systematically the randomised
controlled trial (RCT) evidence for treatment of
macular oedema due to central retinal vein occlusion
(CRVO).
Data sources: MEDLINE, EMBASE, CDSR, DARE,
HTA, NHSEED, CENTRAL and meeting abstracts
( January 2005 to March 2013).
Study eligibility criteria, participants and
interventions: RCTs with at least 12 months of
follow-up assessing pharmacological treatments for
CRVO were included with no language restrictions.
Study appraisal and synthesis methods: 2
authors screened titles and abstracts and conducted
data extracted and Cochrane risk of bias assessment.
Meta-analysis was not possible due to lack of
comparable studies.
Results: 8 studies (35 articles, 1714 eyes) were
included, assessing aflibercept (n=2), triamcinolone
(n=2), bevacizumab (n=1), pegaptanib (n=1),
dexamethasone (n=1) and ranibizumab (n=1). In
general, bevacizumab, ranibizumab, aflibercept and
triamcinolone resulted in clinically significant increases
in the proportion of participants with an improvement
in visual acuity of ≥15 letters, with 40–60% gaining
≥15 letters on active drugs, compared to 12–28% with
sham. Results for pegaptanib and dexamethasone were
mixed. Steroids were associated with cataract
formation and increased intraocular pressure. No
overall increase in adverse events was found with
bevacizumab, ranibizumab, aflibercept or pegaptanib
compared with control. Quality of life was poorly
reported. All studies had a low or unclear risk of bias.
Limitations: All studies evaluated a relatively short
primary follow-up (1 year or less). Most had an
unmasked extension phase. There was no head-to-
head evidence. The majority of participants included
had non-ischaemic CRVO.
Conclusions and implications of key findings:
Bevacizumab, ranibizumab, aflibercept and
triamcinolone appear to be effective in treating macular
oedema secondary to CRVO. Long-term data on
effectiveness and safety are needed. Head-to-head
trials and research to identify ‘responders’ is needed to
help clinicians make the right choices for their patients.
Research aimed to improve sight in people with
ischaemic CRVO is required.
INTRODUCTION
Central retinal vein occlusion (CRVO) is a
vascular disorder of the retina with often
catastrophic consequences to vision and
quality of life.1 2 The incidence of CRVO
increases with age; most individuals affected
are 50 years of age or older.3 It has been esti-
mated that there are around 80 new cases of
CRVO/million population/year.4 5 Although
CRVO most commonly affects one eye, in
around 10% of patients the disease affects
both eyes.2 Approximately 20% of patients
with CRVO will develop large areas of retinal
non-perfusion (ischaemia).6 Furthermore, a
small proportion (around 8%) of patients
with non-ischaemic CRVO may convert into
the ischaemic type during follow-up.6 Retinal
ischaemia may lead to the development of
neovascularisation in the retina, iris or anter-
ior chamber angle. Complications of neovas-
cularisation include vitreous haemorrhage
and neovascular glaucoma.6 Currently, there
is no treatment for ischaemic CRVO other
than that aimed at ameliorating the severity
of complications, with treatments such as
panretinal photocoagulation. Even with the
use of current therapies, some eyes with
ischaemic CRVO end up blind and painful
and, ultimately, enucleation (removal of the
eye) is necessary to provide comfort to
patients.
Not all people with CRVO will require
treatment and macular oedema will resolve
in about a third of those with non-ischaemic
CRVO.2 7 However, most will need treatment
Strengths and limitations of this study
▪ A robust systematic review method was used
which only included randomised controlled
trials.
▪ There were no head-to-head trials and there was
a lack of long-term data on both effectiveness
and safety.
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and the number of options has increased in recent
years. Laser photocoagulation has been, for many years,
the standard therapy for patients with macular oedema
secondary to branch retinal vein obstruction (BRVO).8
However, laser treatment was not found to be beneﬁcial
to those with macular oedema secondary to CRVO9; for
these patients, no therapeutic modalities could be
offered. Recently, several studies have demonstrated the
beneﬁt of antivascular endothelial growth factor (VEGF)
therapies and steroids for the management of patients
with macular oedema secondary to CRVO.10 11 Steroids,
such as triamcinolone and dexamethasone, have anti-
inﬂammatory and antiproliferative attributes (as well as
some anti-VEGF effects) and therefore are primarily
effective by reducing the oedema of the macula.12
Anti-VEGF treatments, such as bevacizumab, ranibizu-
mab, aﬂibercept and pegaptanib, inhibit vascular endo-
thelial growth factor A. In CRVO there is an increase in
vascular endothelial growth factor A which leads to
neovascularisation and oedema.13 In the UK, National
Institute for Health and Care Excellence (NICE) has
approved dexamethasone (in the long-acting form,
Ozurdex) and ranibizumab (Lucentis) and an appraisal
of aﬂibercept is currently underway. Bevacizumab is also
used, but is not licensed for use in the eye; however this
is because the manufacturer has never sought a license,
preferring to market ranibizumab. Triamcinolone has
also been used off license.
An up-to-date review incorporating all drug treatments
for macular oedema secondary to CRVO is needed. The
purpose of this study is to review systematically the ran-
domised controlled evidence for drug treatments of
macular oedema secondary to CRVO.
METHODS
A systematic review was conducted. The following data-
bases were searched: MEDLINE, MEDLINE In-process,
EMBASE (all via OVID); CDSR, DARE, HTA, NHSEED,
CENTRAL (all via The Cochrane Library); Science
Citation Index and Conference Proceedings Citation
Index-Science (via Web of Knowledge). In addition to
the bibliographic database searching, supplementary
searches were undertaken to look for recent and unpub-
lished studies in the WHO International Clinical Trials
Registry Platform and ophthalmology conference web-
sites (American Academy of Ophthalmology, Association
for Research in Vision and Ophthalmology from 2010 to
2012).
Search strategy
An iterative procedure was used to develop two search
strategies with input from previous systematic
reviews.14 15 The ﬁrst search strategy was designed to
retrieve articles reporting randomised controlled trials
(RCTs) or systematic reviews about CRVO published
from 2005 onwards (the publication date of the ﬁrst
RCT on triamcinolone in MEDLINE). Terms for retinal
vein occlusion were included to ensure identiﬁcation of
articles in which BRVO and CRVO were covered, but
were reported separately. The second strategy focussed
on retrieving articles where adverse events of relevant
pharmacological treatments for CRVO were reported.
This second search was limited by condition (age-related
macular degeneration (AMD) or RVO), study type
(RCTs, SRs or observational studies) and date (pub-
lished from 2010 onwards). Searches were conducted in
March 2013. The strategies used in each database are
provided in online supplementary appendix 1. Auto
alerts of searches were set up to capture relevant articles
published after the dates of the searches.
Reference lists from the included studies and identi-
ﬁed systematic reviews were screened.
Inclusion and exclusion criteria
RCTs were used to assess the clinical effectiveness and
adverse events.
Only RCTs examining pharmacological treatment
compared with laser treatment, observation, placebo
(sham injection) or another pharmacological interven-
tion with at least 12 months follow-up were included.
Comparisons of different doses of drugs were not
included unless there was an additional comparator
group as deﬁned above. Studies including CRVO and
BRVO were included provided participants with CRVO
were reported as a subgroup. Studies assessing treat-
ments aimed at restoring circulation to the occluded
vein shortly after onset (<30 days) were excluded. There
were no language restrictions.
Outcomes
The primary outcome was visual acuity measured as
mean change in best-corrected visual acuity (BCVA) or
as proportion of patients improving by 15 Early
Treatment for Diabetic Retinopathy Study (ETDRS)
letters or more. Secondary outcomes included mean
change in macular thickness using optical coherence
tomography (OCT), quality of life and adverse events.
Screening and data extraction
Search results were screened independently by two
authors (CC, JAF and ST). Differences were resolved
through discussion or by consulting a third author
( JAF). Data were extracted by one author (CC and DS)
and checked by a second (ST, CC). Data extraction
included inclusion/exclusion criteria, baseline demo-
graphics, mean change in BCVA, proportion of patients
with 15 letters improvement, central retinal thickness
(CRT) and adverse events. Risk of bias was assessed by
two reviewers using the Cochrane risk of bias tool.16
Meta-analysis was not possible because of a lack of
comparable studies.
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RESULTS
Search results
The study ﬂow is shown in ﬁgure 1. The electronic
searches yielded 518 records. A total of 475 were elimi-
nated based on information in the titles and abstract.
The full text of the remaining 43 records was checked,
and a further eight were eliminated. Reasons for exclu-
sion included the trial being a commentary rather than
an RCT, the study having no relevant comparison group
(dose ranging only), the participants did not have
macular oedema secondary to CRVO, or the interven-
tions being ineligible (non-pharmacological). The
remaining 35 records (including conference abstracts)
reported on eight RCTs of six different pharmacological
agents, and these were included in the analysis. The
Geneva study (2010)11 17 18 technically consists of two
RCTs, but as these were analysed and reported together,
it was counted as one RCT in this analysis.
We also identiﬁed three relevant ongoing trials, one
investigating minocycline (http://clinicaltrials.gov/ct2/
show/study/NCT01468844), one investigating a com-
bination of bevacizumab and triamcinolone (http://




Detailed study characteristics of the included studies are
shown in online supplementary table S1.
Study design
Of the eight included RCTs, six were described as
double-blinded and seven were sham-controlled. All but
one were multicentre. Only one was not funded by
industry. Four trials were international trials, two came
from the USA, and one each from Austria and Sweden.
Six of the trials measured primary endpoints at around
6 months (24–30 weeks), whereas two measured primary
endpoints at 12 months. Five studies reported follow-up
data for up to 12 months, and two reported data for
follow-up periods of up to 2 years.
Participants
The trials randomised a total of 1714 eyes (1 eye/
person). The number of eyes per study ranged between
60 and 437. Follow-up at the primary endpoint ranged
from 77% to 98% (generally over 90% in the interven-
tion groups). The participants had a mean age of
between 59 and 70.5 years, and between 36% and 49%
were female. Only two studies reported mean duration
of macular oedema (4.3 and 4.9 months). Five studies
reported mean time since CRVO diagnosis (range
2.4–2.9 months). Mean baseline BCVA was between 44
and 52.5 ETDRS letters, baseline CRT was between 569
and 721 µm. In most trials, the focus was on macular
oedema secondary to CRVO only, but in the Geneva
trial macular oedema secondary to BRVO and CRVO
was included and only limited data were available on the
CRVO-only group.
Interventions
The Geneva trial (2010 ff.)11 17 18 compared a 0.35 mg
(n=136) and a 0.7 mg dexamethasone (n=154) intravi-
treal implant with sham treatment (n=147). After the
initial 6-month study period, patients could enter a
6-month open label extension, where they received a
0.7 mg dexamethasone intravitreal implant.
The Standard Care versus Corticosteroid for Retinal
Vein Occlusion (SCORE) trial (2009 ff.)19–32 compared
intravitreal injections of 1 or 4 mg of triamcinolone
(∼2 injections over 12 months, n=92 and 91 for 1 and
4 mg, respectively) with an observation group (n=88).
Two forms of triamcinolone have been used in trial; the
SCORE trial used Trivaris, rather than Kenalog. Trivaris
is no longer available because its manufacturer has pro-
moted an alternative steroid (dexamethasone). The
Radial Optic Neurotomy for Central Vein Occlusion
(ROVO) trial (2013)33 compared a single intravitreal
injection of 4 mg of triamcinolone (over 12 months,
n=25) with radial optic neurotomy (n=38) or sham injec-
tion (n=20).
In the Carvedilol Prospective Randomised Cumulative
Survival (COPERNICUS) trial (2012)34 35 intravitreal
injections of 2 mg of aﬂibercept (n=114) were given
every 4 weeks for over 24 weeks to the intervention
group and the comparison group received a sham injec-
tion (n=75). During weeks 24–52, patients in both
groups received aﬂibercept if they met protocol-speciﬁed
retreatment criteria and received a sham injection if
retreatment was not indicated (3.9 SE 0.3 injections in
the sham group and 2.7 SE 0.2 injections in the aﬂiber-
cept group); after the ﬁrst year, patients continued in an
1-year extension phase with as needed dosing. In the
GALILEO trial (2012)36 37 intervention patients also
received intravitreal injections of 2 mg of aﬂibercept
(n=103) every 4 over 24 weeks, while the comparison
group was given sham injections (n=71). During weeks
24–52, patients remained in their original treatment
groups but received their allocated treatment as needed;
beginning from weeks 52 to 76, both groups received
the study drug every 8 weeks.
In a trial by Wroblewski and colleagues,38–44 patients
received 0.3 or 1 mg intravitreal injections of pegaptanib
sodium every 6 for 24 weeks (n=33 and 33), compared
with a sham injection group (n=32). Patients were fol-
lowed up to 52 weeks.
The Central Retinal Vein Occlusion (CRUISE) trial
(2010 ff.)10 45 46 compared monthly injections of 0.3 or
0.5 mg of ranibizumab (n=132 and 130) over 6 months
with sham injection (n=130). During months 6–12, all
patients could receive intraocular ranibizumab (previ-
ously assigned dose or 0.5 mg for the sham group) if
they met prespeciﬁed functional and anatomic criteria;
after 12 months’ follow-up patients could continue in
the Health Outcomes and Reduced Incidence with
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Zoledronic Acid Once Yearly (HORIZON) trial for
another 12 months, where they were eligible to receive
intravitreal injections of 0.5 mg ranibizumab if they ful-
ﬁlled prespeciﬁed criteria.
Epstein et al47–49 conducted an RCT in which they
compared patients receiving four intravitreal injections
of 1.25 mg of bevacizumab (n=30) over 6 months with
patients receiving sham injections (n=30). From 6 to
12 months, all patients received intravitreal bevacizumab
injections every 6 week.
Outcomes
The primary endpoint of all but one study was the pro-
portion with a gain of 15 or more ETDRS letters. The
primary endpoint of the remaining study was mean
change in BCVA. Studies also reported gains or losses of
ETDRS letters at various cut-off points, absolute BCVA,
CRT and safety parameters. The COPERNICUS, the
GALILEO and the CRUISE studies also measured vision-
related quality of life (National Eye Institute Visual
Functioning Questionnaire, NEI-VFQ).10 34–37 45 46
EQ5D was also used in GALILEO.
Ongoing studies
Ongoing trials are shown in online supplementary table
S4, the ﬁrst (clinicaltrials.gov NCT01468844) is a
24-month double-blind RCT from the USA. It set out to
test the safety and effectiveness of minocycline as a treat-
ment for CRVO in around 20 patients with macular
oedema secondary to CRVO. Both groups received
monthly intravitreal bevacizumab injections over 3 months
(and afterwards as needed), and the intervention group
also received 100 mg oral minocycline twice daily over
24 months. The second trial (clinicaltrials.gov
NCT00566761) is an open-label RCT from Mexico in only
around 10 patients assessing whether combined treatment
with bevacizumab and triamcinolone is more effective
than bevacizumab alone. The combination group received
2.5 mg of bevacizumab plus 4 mg of triamcinolone as a
ﬁrst dose and then two doses of bevacizumab alone at
monthly intervals, while the monotherapy group received
three monthly doses of 2.5 mg bevacizumab alone.
Follow-up will be 12 months. A third RCT from Hungary
compares monthly injections of ranibizumab for 3 months
(and as needed thereafter) with Argon laser treatment in
around 40 patients with macular oedema secondary to
CRVO. Follow-up will also be 12 months. The primary end-
point in all studies is BCVA over 12 months.
Risk of bias
Details of risk of bias assessment are shown in online
supplementary table S3.
Most studies (except GALILEO (2012) and Epstein
2012)36 37 47–49 adequately described the generation of
Figure 1 PRISMA statement.
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the allocation sequence, but only half the studies gave
enough details to conﬁrm adequate allocation conceal-
ment. Most studies (unclear in the ROVO 2013 study)33
used at least partial masking, and most studies appeared
to have had masking of outcome assessment. Intention-
to-treat analysis was used in all studies. Where reported
separately for comparison groups, losses to follow-up
tended to be slightly higher for the control groups than
the interventions groups (79–88.5% follow-up in the
control groups and 90–98% in the intervention groups).
All studies appeared to have been free of selective
reporting. Most studies included a power analysis (not
reported for the CRUISE study)10 45 46 but in two cases
(the SCORE and the ROVO studies)19–33 the numbers
randomised were considerably below the numbers indi-
cated in the power calculations. As far as reported, there
were no signiﬁcant differences between comparison
groups in baseline characteristics.
Clinical effectiveness
Detailed study results can be found in online supple-
mentary table S2.
Visual acuity
Figure 2 shows the primary endpoint in most studies,
which was the proportion of participants with a gain of
15 or more ETDRS letters. As there were no signiﬁcant
differences in visual acuity results between groups using
different dosages of the given pharmacological treat-
ment, intervention groups were combined for the sake
of the plot.
In the Geneva trial (2010 ff.)11 17 18 treatment of
macular oedema secondary to CRVO with a 0.7 mg intra-
vitreal dexamethasone implant resulted in a 0.1 letter
gain in BCVA compared to a loss of 1.8 in the sham
group (p<0.001). The difference persisted in the exten-
sion period where all patients received the 0.7 mg
dexamethasone implant. However, there was no signiﬁ-
cant difference in the proportion of patients gaining or
losing 15 letters at either 6 or 12 months (0.35 or 0.7 mg
dexamethasone). This may reﬂect the timing of peak
effect at 90 days with dexamethasone.
In the SCORE trial (2009 ff.),19–32 patients in the
triamcinolone groups lost signiﬁcantly fewer ETDRS
letters (triamcinolone 1 mg 1.2 letters loss, 4 mg 1.2
letters loss and observation 12.1 letters loss) over both
12 and 24 months than patients in the observation
group. The proportion of patients gaining 15 letters or
more was also signiﬁcantly larger in the intervention
groups at 12 and 24 months (25.6% compared with
6.8% and 31% compared with 9%, respectively). The
proportion of patients receiving triamcinolone and
losing 15 letters or more was smaller (25.6%) than in
the observation group (43.8%), but this difference was
not statistically signiﬁcant (p=0.06).
There was some overall improvement in BCVA in both
intervention groups at 12 months in the ROVO trial
(201333; triamcinolone 20%, radial optic neurotomy
47% and sham 10%); however, it was unclear whether
there were any statistically signiﬁcant differences
between the 4 mg triamcinolone, the radial optic neur-
otomy or the sham group. However, there were signiﬁ-
cantly more patients with an improvement of more than
or equal to 15 letters in the neurotomy group than in
the sham group (47% vs 10%), but no signiﬁcant differ-
ence to sham after one dose of triamcinolone.
In the COPERNICUS (2012)34 35 and GALILEO
(2012)36 37 trials, patients in the aﬂibercept group had a
signiﬁcant improvement in BCVA at 6 months of 18 and
17.3 letters (compared with 4 letters loss and 3.3 letter
gain in sham groups, respectively) and this was main-
tained at 12 months and was signiﬁcantly greater than
the improvements in the sham groups. This was paral-
leled by a signiﬁcantly greater proportion of patients
Figure 2 Study results for the
primary outcome (≥15 Early
Treatment for Diabetic
Retinopathy Study letter gain).
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(56.1% compared with 12.3% and 60.2% compared with
22.1%, respectively) gaining 15 letters or more. Patients
treated sooner after diagnosis (less than vs more than
2 months) seemed to beneﬁt more (in terms of propor-
tion of patients with 15 letters or more gain) in both
trials.
The increase in mean change in BCVA with 0.3 mg
pegaptanib compared with sham did not reach signiﬁ-
cance at 30 weeks in the trial by Wroblewski and collea-
gues,38–44 but there was a greater increase in BCVA with
1 mg pegaptanib compared with sham (9.9 letter gain
compare with 3.2 letter loss). These differences were not
statistically signiﬁcant at 52 weeks. There was no signiﬁ-
cant difference between any of the groups in the propor-
tion of patients gaining 15 letters or more at 30 weeks,
but signiﬁcantly fewer patients in both dosage groups
lost 15 letters or more than in the sham group (6% com-
pared with 31%).
In the CRUISE trial (2010 ff.)10 45 46 mean change in
BCVA was signiﬁcantly increased in the ranibizumab
groups (no difference between doses) compared with
the sham group at 6 and 12 months (12 letters gained in
the 0.5 mg group compared with 7.6 in the sham
group). After the 1 year extension with ranibizumab as
needed in all groups, there was no difference between
the doses of ranibizumab at 24 months. The pattern was
similar for the proportion of patients gaining 15 letters
or more.
In the trial by Epstein et al,47–49 treatment with intravi-
treal bevacizumab, compared with sham treatment sig-
niﬁcantly increased mean change in BCVA (14.1 letters
gain compared with 2 letters lost) and the proportion of
patients gaining 15 letters or more (60% compared to
20%) at 24 weeks. This difference was maintained in the
extension period, even though both groups had been
receiving bevacizumab. Younger patients (<70 years)
tended to have better visual outcomes than older
patients (>70 years).
Central retinal thickness
In the Geneva trial (2010 ff.)11 17 18 no signiﬁcant differ-
ence was found in the reduction of CRT after 6 months
of treatment in patients with macular oedema secondary
to CRVO with the 0.7 mg intravitreal dexamethasone
implant (no data given for the 0.35 mg implant) com-
pared with sham.
In the SCORE trial (2009 ff.),19–32 CRT decreased in
all study groups, but there was no signiﬁcant difference
between groups at either 12 or 24 months. Similarly,
there was no clear difference in the proportion of
patients achieving a CRT of less than 250 µm. CRT
decreased in all comparison groups in the ROVO trial
(2013)33 but there was no signiﬁcant difference between
groups.
In the COPERNICUS trial (2012)34 35 and in the
GALILEO trial (2012)36 37 there was a signiﬁcantly
greater reduction in CRT at 6 months in the aﬂibercept
group than in the control group. However, the
signiﬁcant difference was maintained in the longer term
only in the GALILEO trial, where patients continued
their assigned treatment up to 12 months. In the
COPERNICUS trial, patients in the sham group also
received aﬂibercept in the extension period, which
caused a similar decrease in CRT as in the original inter-
vention group.
After 30 weeks of treatment with pegaptanib
(Wroblewski and colleagues),38–44 differences in
decrease of CRT versus sham did not reach signiﬁcance,
but at 52 weeks, the decrease in CRT was signiﬁcantly
greater in both the 0.3 mg and the 1 mg pegaptanib
groups compared with sham.
After treatment with ranibizumab in the CRUISE trial
(2010 ff.)10 45 46 a signiﬁcant reduction in CRT was
observed and signiﬁcantly more patients achieved a CRT
of 250 µm or less in the intervention groups (no differ-
ence between doses) than in the sham group at
6 months. This difference did not persist at 12 and
24 months because all groups received ranibizumab as
needed.
In the trial by Epstein et al,47–49 treatment with intravi-
treal bevacizumab signiﬁcantly decreased CRT and the
proportion of patients with no residual oedema (CRT
<300 µm) at 24 weeks, compared with sham treatment.
When both groups received bevacizumab in the exten-
sion period, similar decreases in CRT and increases in
the proportion of patients with no residual oedema were
seen.
Vision-related quality of life
Vision-related quality of life (NEI-VFQ25) was signiﬁ-
cantly higher in the aﬂibercept group, compared with
sham injection, at 6 months in the COPERNICUS trial
(+7.2 compared with +0.8)34 35 and the GALILEO trial
(+7.5 compared with +3.5).36 37 In the COPERNICUS
trial, patients in the sham group who received aﬂiber-
cept in the extension period had a similar increase in
vision-related quality of life as patients in the original
intervention group by 12 months.
In the CRUISE trial (2010 ff.)10 45 46 vision-related
quality of life (NEI-VFQ) was similarly increased in both
ranibizumab groups and statistically signiﬁcantly more
than in the sham group at 6 months (+6.2 compared
with +2.8). At 12 months, with all groups receiving rani-
bizumab as needed, the increases were similar in all
three groups.
Adverse events
The 0.7 mg dexamethasone intravitreal implant caused
signiﬁcantly more increased intraocular pressure (IOP)
than sham treatment (30.1% vs 1.4% in the control
group) in patients with CRVO in the Geneva trial (2010
ff.11 17 18; not reported for 0.35 mg). The incidence of
cataract was also slightly higher in the dexamethasone
group but numbers were small because of the short dur-
ation. There were no other differences in adverse events
between groups.
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In the triamcinolone group (especially 4 mg, SCORE
trial 2009 ff.),19–32 there was a higher increase in IOP,
lens opacity onset or progression (at 12 months) and
cataract surgery (12–24 months) than in the control
group. There were no other differences in adverse
events between groups. A similar tendency was seen in
the ROVO trial (2013).33
Aﬂibercept did not appear to increase the incidence
of ocular or non-ocular adverse events compared with
sham in both the COPERNICUS trial (2012)34 35 and
the GALILEO trial (2012).36 37
In the trial by Wroblewski and colleagues,38–44 adverse
events in response to pegaptanib were not reported in
detail, but there do not appear to have been any serious
ocular or systemic adverse events.
After treatment with ranibizumab in the CRUISE trial
(2010 ff.)10 45 46 there were no consistent differences in
ocular or systemic adverse events between the interven-
tion groups. None of the ocular adverse events appeared
to have increased substantially after all patients received
ranibizumab up to 24 months.
Epstein et al47–49 did not report adverse events in
response to bevacizumab in detail, but the treatment
appears not to have caused any serious ocular adverse
events over 48 weeks.
DISCUSSION
Statement of principal findings
Evidence from good quality RCTs shows that intravitreal
steroids and anti-VEGF therapies increase the propor-
tion of patients whose vision improves by 15 or more
letters in patients with macular oedema secondary to
CRVO. The most effective drugs result in over 60% of
patients gaining 15 letters compared with only about
20% of the control groups. The RCT evidence shows
only short-term effectiveness of ranibizumab, bevacizu-
mab, aﬂibercept and triamcinolone. Results from trials
of dexamethasone and pegaptanib were mixed.
Long-term evidence is awaited.
Strengths and limitations
A robust systematic review methodology was used. A
broad search strategy was implemented, which included
not restricting the search strategy with drug terms. Grey
literature was searched by screening meeting abstracts
from relevant conferences. There were no language
restrictions. Two reviewers screened titles and abstracts
and conducted data extraction and risk of bias assess-
ment. Risk of bias was assessed using the Cochrane Risk
of Bias Tool and was generally judged to be low or
unclear. Only studies with 1-year follow-up were included
to exclude studies with very short follow-up RCTs were
identiﬁed for all the new ophthalmological drugs,
except for the steroid, ﬂuocinolone.
The main limitation is the short duration of follow-up.
The primary outcome for most trials was measured at
6 months, with an extension phase of up to 12 months.
Hence, it is not known whether the beneﬁt of these
treatments will be maintained long term. Furthermore,
potential side effects of these treatments may not be cap-
tured in these studies as a result of their short follow-up.
Patients and clinicians would like sustained, life-long
improvement in visual acuity, but of all included studies
only one of them had a follow-up of over 24 months.
The sample size of some studies was small. For
example, the evidence for pegaptanib and bevacizumab
comes from studies with around 30 participants/arm
which substantially increases the risk of a type II error.
Only three trials included quality of life data, arguably
one of the most important outcomes.
The proportion of participants and severity of ischae-
mia within the trials was not clear. While ischaemia is
not mentioned in the inclusion/exclusion criteria of
most studies, these participants were unlikely included
in these studies, especially if the diagnosis of ischaemic
CRVO is based on strict criteria. Furthermore, patients
were entered into the trials relatively soon after diagnosis
(mean 4.3–4.9 months) and it is not clear if the effects
would be similar in patients who present with long-
standing disease.
Another limitation was that patients were not asked at
the trials, what treatment they thought they had
received, which would have provided data on the success
of masking of allocation.
In the case of dexamethasone, the results at 6 months
were not as good as at 90 days, because of the duration
of action. Earlier retreatment, at say 120 days, would
have improved results, but many clinicians might be
reluctant to repeat injections of dexamethasone implant
often because of the large needle size and risk of
adverse effects.
Adverse events
Results from the included studies clearly demonstrate
that steroids (triamcinolone and dexamethasone) are
associated with clinically meaningful increases in IOP
and cataract progression. Anti-VEGF therapy ocular
adverse events reported in the trials were similar in both
placebo and intervention arms.
There is limited evidence of the safety of these drugs
speciﬁcally in CRVO, but it would not be unreasonable
to look to trials in neovascular AMD and diabetic
macular oedema (DMO) for safety data, where there is
more experience. The comparison of AMD treatment
trial, which compared bevacizumab with ranibizumab in
AMD, suggested that there was a higher incidence (rela-
tive risk (RR) 1.29; 95% CI 1.01 to 1.66) of serious sys-
tematic adverse events (primarily hospitalisations) in the
bevacizumab arm.50 Some have raised concerns about
arterial thromboembolic events with bevacizumab, but
none of these has been demonstrated in the published
literature.51–54 Micieli et al55 undertook a systematic
review of the adverse events associated with bevacizu-
mab. Twenty-two studies were reviewed, representing
12 699 participants.55 Adverse events in patients treated
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with bevacizumab were cerebrovascular events (0.21%),
myocardial infarction (0.19%) and increased blood pres-
sure (0.46%). Most of these represent the background
burden of disease in patients with advanced eye disease.
The proportion of these directly attributable to bevacizu-
mab is likely to be very small. Campbell et al51 undertook
a nested case–control study of over 7000 cases and
37 000 controls. Ranibizumab and bevacizumab injec-
tion was the exposure and cardiovascular events were
the outcome. The authors found that ranibizumab and
bevacizumab were not associated with increased cardio-
vascular events.
Increased IOP has been associated with ranibizumab,
bevacizumab and pegaptanib. Sustained increased in
IOP has estimated to be 5.5–6% with these drugs.56 57
Robust evidence on the long-term safety of aﬂibercept
is awaited.
What do these results mean?
Until very recently, patients with macular oedema as a
result of CRVO could only be offered visual rehabilita-
tion and visual aids in an attempt to help them to deal
better with their reduced vision and its implications in
their daily activities and quality of life. Their future is
brighter now as new options to treat macular oedema
have become available. Triamcinolone is likely to be a
cost-effective treatment at least in selected groups of
patients, such as pseudophakic individuals or those with
pre-existing cataracts that may require cataract surgery in
the near future. The lack of a commercially available
licensed product for intraocular administration may
restrict its use in clinical practice.
Some anti-VEGF therapies, including bevacizumab,
ranibizumab and aﬂibercept, have also been shown to
be effective in short-term studies for the treatment of
patients with macular oedema and CRVO. Bevacizumab
has the advantage of having a low cost, with an appar-
ently similar effect to other anti-VEGF therapies50 58 59
but there is some reluctance to use it as it is not licensed
for use in the eye. This has been seen in other eye con-
ditions, such as AMD and DMO. Aﬂibercept, requiring
potentially fewer injections than other anti-VEGF agents,
could represent an advantage to patients and may
relieve pressure on ophthalmology clinics. Healthcare
systems will need to evaluate the cost-effectiveness of
these new treatments and support affordable ones. The
NICE is currently appraising aﬂibercept. Policy makers
are left in a difﬁcult position because of bevacizumab. It
is cheaper than all other drugs60 and appears to be as
effective, but is unlicensed and unlike ranibizumab and
aﬂibercept does not have evidence from large, well-
funded RCTs in CRVO. The use of bevacizumab would
result in considerable savings for the NHS.
It is important to note that the evidence of beneﬁt of
these new therapies is likely to only apply to patients
with non-ischaemic CRVO. Although some patients with
ischaemic CRVO were included, these individuals are
likely to have mild ischaemic CRVO. Thus, for patients
with established ischaemic CRVO, there are no proven
treatments available and further research into this area
is very much needed.
What is the context of these results
Earlier systematic reviews identiﬁed limited evidence on
the clinical effectiveness of treatments. A review by
Braithwaite et al61 (search date August 2010) on anti-VEGF
agents identiﬁed one RCT10 45 46 comparing two doses of
ranibizumab and one RCT38–44 comparing two doses of
pegaptanib sodium versus placebo or no treatment. In
both RCTs, the higher dose of the anti-VEGF signiﬁcantly
improved BCVA compared with sham injection in the
short term (∼6 months), but the effects in the longer term
were unclear. Braithwaite and colleagues concluded that
data from the two RCTs could not be synthesised because
ranibizumab and pegaptanib sodium might not be directly
comparable. Subsequent RCTs identiﬁed in this review
also suggest beneﬁt in ocular outcomes in macular
oedema secondary to non-ischaemic CRVO for the
anti-VEGFs bevacizumab and aﬂibercept.34–37 47–49
Gewaily and Greenberg62 reviewed the literature on
intravitreal corticosteroids (search date November 2008)
versus observation in macular oedema secondary to
CRVO and identiﬁed no relevant RCTs. Results from
two observational studies suggested that triamcinolone
acetonide might be beneﬁcial in the treatment of
macular oedema secondary to non-ischaemic CRVO.
However, as the authors of the review caution because
conclusions are primarily drawn from small case series
and case reports with short follow-up. Results from the
SCORE 2009 RCT corroborate the observational
studies.19–32 The effects of triamcinolone acetonide in
people with non-ischaemic CRVO without associated
macular oedema are less clear. Data from four observa-
tional studies led Gewaily and Greenberg to conclude
that intravitreal corticosteroids are associated with transi-
ent anatomical and functional improvements.
Immediate treatment aimed at relieving the blocked
vein and surgical interventions were out with the remit
of this review. Antithrombotics, such as low-molecular
weight heparin (LMWH), and ﬁbrinolytics have also
been found to beneﬁt visual acuity in retinal vein occlu-
sion with no associated macular oedema. Two systematic
reviews63 64 identifying the same three RCTs in recent
onset (≤30 days) BRVO or CRVO found that LMWH
improved visual acuity compared with aspirin and that
the associated beneﬁt was larger in CRVO; only one of
the three RCTs included people solely with CRVO. One
review64 also included one RCT comparing ticlopidine
with placebo and two RCTs assessing intravenous ﬁbrino-
lytic therapy followed by warfarin or aspirin with either
haemodilution or no treatment. The authors of the
reviews conclude that no deﬁnitive recommendations
can be made on clinical effectiveness of LMWH in
CRVO given the limited evidence available.
Radial optic neurotomy involves the performance of a
radial cut using a microvitreoretinal blade through the
8 Ford JA, Clar C, Lois N, et al. BMJ Open 2014;4:e004120. doi:10.1136/bmjopen-2013-004120
Open Access
 group.bmj.com on August 26, 2014 - Published by bmjopen.bmj.comDownloaded from 
lamina cribrosa, scleral ring and adjacent sclera at a
selected point in the optic nerve head with the goal of
‘decompressing’ the scleral outlet (space conﬁned by
the scleral ring and containing the lamina cribrosa, the
central retinal artery, central retinal vein and the optic
nerve). The ROVO trial found radial optic neurotomy to
be more effective than sham.
While this review was being considered for publica-
tion, another was published, with differences in scope
(BRVO and CRVO) and inclusions (this review is more
up-to-date).65 The reviewers found that aﬂibercept and
bevacizumab resulted in greatest gain, followed by rani-
bizumab and triamcinolone. The overall conclusions in
both reviews were similar.
Further research
Large adequately powered RCTs comparing ranibizu-
mab, bevacizumab, aﬂibercept and triamcinolone are
needed. Part of the problem is that the US Food and
Drug Administration requires pharmaceutical companies
to present data establishing a drug’s safety and effective-
ness. While this does not speciﬁcally require a placebo-
controlled trial, it is the most efﬁcient study design for
demonstrating effectiveness and safety. Clinicians and
researchers are left with placebo-controlled trials dem-
onstrating effectiveness for individual drugs, but a lack
of evidence to help them decide which is best for their
patients.
Given the cost of these treatments and the burden of
repeated injections to patients and healthcare systems,
research aiming to predict ‘responders’ would be useful
as at present this is performed by therapeutic trials.
Treatments could then be targeted to patients likely to
beneﬁt. Research is also needed on the frequency and
sequences of drugs. As other pathogenic pathways
besides inﬂammation and VEGF-mediated pathways may
be implicated in the development of macular oedema in
patients with CRVO, these should be investigated in an
attempt to develop new therapeutic strategies for this
condition. Research is also needed into optimum timing
of treatment after CRVO. The cost-effectiveness of diag-
nostic technologies for determining when retreatment is
necessary should be examined.
We also need better treatments since a signiﬁcant pro-
portion of patients do not improve with all of these drugs.
Future RCTs should include longer term outcomes, as
functional results observed at 6 months or even 1 year
may not necessarily be representative of what is likely to
be achieved longer term and, furthermore, potential
side effects of treatments, such as retinal atrophy after
repeated injections of anti-VEGFs, may not be captured
in short-term studies.
CONCLUSIONS
Bevacizumab, ranibizumab, aﬂibercept and triamcino-
lone appear to be effective in improving the number of
patients who gain 15 letters or more in CRVO. There
are mixed results for dexamethasone and pegaptanib.
Steroids were associated with cataract progression and
increased IOP. Long-term data on effectiveness and
safety are needed. Head-to-head trials and research to
identify ‘responders’ is needed to help clinicians make
the right choices for their patients.
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